Drugs to elicit induced regulatory T cell (iTreg) responses might be valuable as immunosuppressive therapies in transplantation or autoimmunity, whereas drugs to suppress iTregs could be useful in cancer or chronic infection. A rugged flow cytometry-based drug-screening assay to quantify conversion of conventional T cells to FoxP3+ Tregs by human regulatory macrophages (Mreg) has been established. This system enables an unbiased approach to discovery of novel mechanisms controlling human iTreg development, stability and function.
Spreker: James Hutchinson, University Hospital Regensburg
Dit webinar vindt plaats op dinsdag 20 april om 10:00
